Chau KHY, et al. - To determine the trends in the US of bioresorbable vascular scaffolds (BVS) use after device approval to explain changes in response to further releases of data and US Food and Drug Administration (FDA) warnings, researchers studied a total of 682,951 patients who participated in the trials, of which 471,064 were male, 587,301 were white, and mean age was 62.6 years for BVS and 65.7 years for conventional stents. Patients with less comorbidities and lower-acuity presentations were more likely to be implanted with BVS vs conventional stents. The majority of US physicians and hospitals were selective in using BVS mostly in patients comparable to those in the approval trial. After negative results were released, declines were noticed in the BVS in the ensuing months, which is an appropriate physician response to adverse data updates and FDA warnings.